My Profile

Search abstracts

Lewis Sheiner


2018
Montreux, Switzerland



2017
Budapest, Hungary

2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
KÝbenhavn, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland



Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

Reference:
PAGE 26 (2017) Abstr 7413 [www.page-meeting.org/?abstract=7413]


PDF poster/presentation:
Click to open Click to open

Oral: Benefit-Risk assessment


B-05 Kevin Marsh Current practices and gaps in benefit-risk assessment: opportunities for combining MCDA with model-based approaches

Kevin Marsh

Evidera

Objectives:

  • Provide an overview of the use of quantitative BRA by the FDA.
  • Illustrate how quantitative BRA is undertaken by industry to demonstrate the value of technologies.
  • Illustrate how quantitative BRA can be incorporated into model-based approaches to trial design. 
  • Identify the challenges, and potential solutions to using quantitative BRA to inform trial design.

Overview/Description of presentation: Industry’s use of quantitative benefit-risk assessment (BRA) has recently received stimulus from an increased interest in its use by the FDA. Most BRA is thus undertaken by industry alongside phase 3 trials. However, there is increasing interest in undertaking BRA earlier in the development process, incorporating BRA into model-based approaches to informing the design of trials. This will allow the assessment of trial design scenarios to be based on models of the probability of achieving regulatory approval.

The presentation will be organised into four sections:

  1. A definition of quantitative BRA, how this differs from other types of BRA, and how MCDA supports quantitative BRA.
  2. A summary of FDA requirements and guidelines for quantitative BRA, and an illustration of a BRA used in an FDA approval decision.
  3. An outline of how quantitative BRA could be incorporated into model-based approaches to trial design.
  4. An outline of key considerations when designing a quantitative BRA for incorporation into model-based approaches to trial design, including dealing with uncertainty in performance ranges, and generating weights for longer lists of treatment attributes.

Conclusions/Take home message: Quantitative BRA is increasingly being used to support approval in the US. Anticipating this requirement, it is possible to incorporate quantitative BRA into model-based approaches to trial design.